{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:03:46Z","timestamp":1764306226889,"version":"3.40.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA271597","R01CA281216","P30CA086862","P30CA023168","UH3CA262220"],"award-info":[{"award-number":["R01CA271597","R01CA281216","P30CA086862","P30CA023168","UH3CA262220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Metastatic breast cancer (MBC) remains a therapeutic challenge due to the persistence of minimal residual disease (MRD) and tumor recurrence. Herein we utilize a model of MBC that is sensitive to inhibition of fibroblast growth factor receptor (FGFR), resulting in robust regression of pulmonary lesions upon treatment with the FGFR inhibitor pemigatinib. Assessment of the remaining MRD revealed upregulation of platelet-derived growth factor receptor (PDGFR). Functionally, we demonstrate increased response to PDGF ligand stimulation following pemigatinib treatment. Depletion of PDGFR did not alter tumor growth under control conditions but did delay tumor recurrence following a treatment window of pemigatinib. To overcome this therapeutic hurdle, we found that inhibition of DNA methyltransferase 1 (DNMT1) prevents pemigatinib-induced cellular plasticity. Combined targeting of FGFR and DNMT1 prevented induction of PDGFR, enhanced pulmonary tumor regression, slowed tumor recurrence, and prolonged survival. These findings enhance our understanding of cellular plasticity during states of treatment-induced MRD and suggest that inhibition of DNA methylation could augment current approaches being used to treat MBC.<\/jats:p>","DOI":"10.1038\/s41419-025-07591-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:44:34Z","timestamp":1743831874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Growth factor receptor plasticity drives therapeutic persistence of metastatic breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Mitchell","family":"Ayers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvis","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneesha","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie W.","family":"Reeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-1469","authenticated-orcid":false,"given":"Emily","family":"Dykhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameek","family":"Roychowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-7413","authenticated-orcid":false,"given":"Michael K.","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"7591_CR1","doi-asserted-by":"crossref","unstructured":"Winters S, Martin C, Murphy D, Shokar NK. Chapter One - Breast Cancer Epidemiology, Prevention, and Screening. In: Lakshmanaswamy R, editor. Progress in Molecular Biology and Translational Science [Internet]. Academic Press; 2017 [cited 2023 Sep 27]. 1\u201332. (Approaches to Understanding Breast Cancer; vol. 151). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1877117317301126.","DOI":"10.1016\/bs.pmbts.2017.07.002"},{"key":"7591_CR2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1381612821666141211120604","volume":"21","author":"M Luo","year":"2015","unstructured":"Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des. 2015;21:1301\u201310.","journal-title":"Curr Pharm Des"},{"key":"7591_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00441-011-1199-1","volume":"347","author":"MK Wendt","year":"2012","unstructured":"Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-\u03b2-induced EMT during cancer progression. Cell Tissue Res. 2012;347:85\u2013101.","journal-title":"Cell Tissue Res"},{"key":"7591_CR4","volume":"12","author":"N Xie","year":"2020","unstructured":"Xie N, Tian C, Wu H, Yang X, liu L, Li J, et al. FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. Ther Adv Med Oncol. 2020;12:1758835920915305.","journal-title":"Ther Adv Med Oncol"},{"key":"7591_CR5","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1535-7163.MCT-16-0136","volume":"15","author":"WS Brown","year":"2016","unstructured":"Brown WS, Tan L, Smith A, Gray NS, Wendt MK. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol Cancer Ther. 2016;15:2096\u2013106.","journal-title":"Mol Cancer Ther"},{"key":"7591_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00213-5","volume":"7","author":"SS Akhand","year":"2021","unstructured":"Akhand SS, Chen H, Purdy SC, Liu Z, Anderson JC, Willey CD, et al. Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. npj Breast Cancer. 2021;7:1\u201311.","journal-title":"npj Breast Cancer"},{"key":"7591_CR7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4143\/crt.2023.468","volume":"55","author":"HY Min","year":"2023","unstructured":"Min HY, Lee HY. Cellular dormancy in cancer: mechanisms and potential targeting strategies. Cancer Res Treat. 2023;55:720\u201336.","journal-title":"Cancer Res Treat"},{"key":"7591_CR8","doi-asserted-by":"crossref","unstructured":"Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 2024;43:197\u2013228.","DOI":"10.1007\/s10555-024-10172-z"},{"key":"7591_CR9","doi-asserted-by":"publisher","unstructured":"Pietras K, Sj\u00f6lund J. Cellular plasticity in the breast cancer ecosystem. Ups J Med Sci. 2024;129. https:\/\/doi.org\/10.48101\/ujms.v129.10629.","DOI":"10.48101\/ujms.v129.10629"},{"key":"7591_CR10","doi-asserted-by":"crossref","unstructured":"Akhand SS, Liu Z, Purdy SC, Abdullah A, Lin H, Cresswell GM, et al. Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade. Cancer Immunol Res. 2020;8:1542\u201353.","DOI":"10.1158\/2326-6066.CIR-20-0235"},{"key":"7591_CR11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1541-7786.MCR-23-0955","volume":"22","author":"E Kulkoyluoglu Cotul","year":"2024","unstructured":"Kulkoyluoglu Cotul E, Safdar MH, Paez SJ, Kulkarni A, Ayers MG, Lin H, et al. FGFR1 signaling facilitates obesity-driven pulmonary outgrowth in metastatic breast cancer. Mol Cancer Res. 2024;22:254\u201367.","journal-title":"Mol Cancer Res"},{"key":"7591_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-023-05690-5","volume":"7","author":"H Lin","year":"2024","unstructured":"Lin H, Hassan Safdar M, Washburn S, S. Akhand S, Dickerhoff J, Ayers M, et al. Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer. Commun Biol. 2024;7:1\u201311.","journal-title":"Commun Biol"},{"key":"7591_CR13","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41388-021-01685-w","volume":"40","author":"H Yoon","year":"2021","unstructured":"Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, et al. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene. 2021;40:1957\u201373.","journal-title":"Oncogene"},{"key":"7591_CR14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Seminars Cancer Biol. 2021;72:198\u2013213.","journal-title":"Seminars Cancer Biol"},{"key":"7591_CR15","doi-asserted-by":"crossref","first-page":"116559","DOI":"10.1016\/j.biopha.2024.116559","volume":"174","author":"L Trnkova","year":"2024","unstructured":"Trnkova L, Buocikova V, Mego M, Cumova A, Burikova M, Bohac M, et al. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies. Biomedicine Pharmacother. 2024;174:116559.","journal-title":"Biomedicine Pharmacother"},{"key":"7591_CR16","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380.","journal-title":"Science"},{"key":"7591_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16490","volume":"529","author":"WA Flavahan","year":"2016","unstructured":"Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529:110\u20134.","journal-title":"Nature"},{"key":"7591_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8:113.","journal-title":"Signal Transduct Target Ther"},{"key":"7591_CR19","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.3390\/cancers15235605","volume":"15","author":"MN Wicker","year":"2023","unstructured":"Wicker MN, Wagner KU. Cellular plasticity in mammary gland development and breast cancer. Cancers. 2023;15:5605.","journal-title":"Cancers"},{"key":"7591_CR20","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12:4564\u201380.","journal-title":"Theranostics"},{"key":"7591_CR21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2020;9:338\u201357.","journal-title":"Liver Cancer"},{"key":"7591_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10:2977.","journal-title":"Nat Commun"},{"key":"7591_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","volume":"4","author":"RF Sweis","year":"2016","unstructured":"Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the non\u2013T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4:563\u20138.","journal-title":"Cancer Immunol Res"},{"key":"7591_CR24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","volume":"7","author":"S Palakurthi","year":"2019","unstructured":"Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, et al. The combined effect of FGFR Inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7:1457\u201371.","journal-title":"Cancer Immunol Res"},{"key":"7591_CR25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ncb3355","volume":"18","author":"T Welte","year":"2016","unstructured":"Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, et al. Oncogenic mTOR signaling recruits myeloid-derived suppressor cells to promote tumor initiation. Nat Cell Biol. 2016;18:632\u201344.","journal-title":"Nat Cell Biol"},{"key":"7591_CR26","doi-asserted-by":"crossref","unstructured":"Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, et al. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024;10:1565\u201370.","DOI":"10.1001\/jamaoncol.2024.3900"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07591-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:45:19Z","timestamp":1743831919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07591-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7591"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07591-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}